<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03933410</url>
  </required_header>
  <id_info>
    <org_study_id>K020-218</org_study_id>
    <nct_id>NCT03933410</nct_id>
  </id_info>
  <brief_title>UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder</brief_title>
  <acronym>UNLOCKED</acronym>
  <official_title>A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects With A Urea Cycle Disorder With Inadequate Control on Standard of Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaleido Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaleido Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      UNLOCKED: A Phase 2 Trial to Evaluate the Efficacy and Safety of KB195 in Subjects with a
      Urea Cycle Disorder with Inadequate Control on Standard of Care
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We expect the trial to enroll approximately 24 Urea Cycle Disorder (UCD) patients on standard
      of care with elevated ammonia levels. The planned treatment duration is eight weeks, with a
      primary endpoint of proportion of subjects who achieve a ≥15% reduction from baseline in
      fasting ammonia at the end of treatment. Patients will also be followed for safety and
      tolerability. This clinical trial is intended to allow us to evaluate efficacy of KB195 in
      reducing ammonia in UCD patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2019</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>K020-218 is a single arm, open-label study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects who achieve a ≥15% reduction from baseline in fasting plasma ammonia at the end of treatment.</measure>
    <time_frame>Day -1 to Day 55</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects normalizing their fasting plasma ammonia concentrations from above the upper limit of normal at baseline to below the upper limit of normal at the end of treatment.</measure>
    <time_frame>Day -1 to Day 55</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events (AEs)</measure>
    <time_frame>Day -28 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing severe adverse events (SAEs)</measure>
    <time_frame>Day -28 to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of treatment in Gastrointestinal Tolerability Questionnaire (GITQ) scores</measure>
    <time_frame>Day -28 to Day 84</time_frame>
    <description>Evaluate the effect of KB195 on self-report questionnaires including the Gastrointestinal Tolerability Questionnaire, an assessment of the frequency and severity of GI symptoms, e.g., gas, abdominal pain, calculated on a scale from 0 (None/Not applicable) to a maximum score of 60 (Severe/Much more than usual) for all questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to end of treatment in Bristol Stool Scale (BSS) scoring.</measure>
    <time_frame>Day -28 to Day 84</time_frame>
    <description>Evaluate the effect of KB195 on self-report questionnaires including the Bristol Stool Scale, an assessment of stool consistency on a scale from 1 (separate hard lumps, like nuts, hard to pass) through 7 (watery, no solid pieces, entirely liquid)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Urea Cycle Disorder</condition>
  <arm_group>
    <arm_group_label>KB195</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KB195 is a novel glycan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KB195</intervention_name>
    <description>KB195 is a novel glycan</description>
    <arm_group_label>KB195</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Signed informed consent and willing to comply with protocol-specified procedures.

          -  Has any confirmed UCD other than N-acetyl glutamatesynthase (NAGS) deficiency.

          -  Is male or female, 12 to 70 years of age (inclusive)

          -  If ≥ 18 years old, has a BMI ≥20.0 and &lt; 40.0 kg/m2. If &lt; 18 years old, has a BMI
             between 5th percentile and 95th percentile and weight greater than 5th percentile
             according to age, sex and regionally appropriate growth chart

          -  Has evidence of poorly controlled disease on the current standard of care (SOC)

          -  If NBT is part of SOC, is on a stable dose and regimen for at least 4 weeks before
             Screening and the dose is expected to remain stable during the study

          -  Is willing to maintain a stable diet throughout the course of study and is willing to
             continue usual exercise routine.

          -  If taking probiotics or prebiotics, is on a stable dose regimen for at least 4 weeks
             before Screening and the dose and regimen are expected to remain stable during the
             study

          -  Has a negative urine screen for drugs of abuse at Screening

          -  If male or female of child bearing potential, agree with use effective method of
             contraception for the duration of the study and 90 days after last dose of study
             product

        Key Exclusion Criteria:

          -  Is at a high risk for metabolic decomposition.

          -  Has had a substantive change in diet or any other aspect of UCD management within 4
             weeks before the Screening Visit

          -  Has used a systemic anti-infective within 4 weeks before the Screening Visit, or use
             is anticipated during the study

          -  Has been diagnosed with Citrullinemia Type II

          -  Is receiving any systemically administered immunosuppressant medication on a chronic
             basis

          -  Has changed the use of or dose of any drug or other compound to modulate GI motility
             within 4 weeks before the Screening Visit, or the use or dose is expected change
             during the course of the study

          -  Has a history of or active GI or liver disease

          -  Has a prior solid organ transplantation including liver transplantation, or is
             anticipated to receive a liver transplant during study participation

          -  Has used an investigational drug, product, or device within 30 days before the
             Screening Visit

          -  Has a contraindication, sensitivity, or known allergy to the study drug

          -  Is considered, in the opinion of the PI, to likely be a poor attendee or unlikely for
             any reason to be able to comply with the study drug procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kaleido Biosciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Wingertzahn, PhD</last_name>
    <phone>(617) 674-9000</phone>
    <email>clinicalstudies@kaleido.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicholas Ah Mew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida/ USF HEALTH</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Gonzalez</last_name>
      <phone>813-259-8813</phone>
      <email>egonzal2@usf.edu</email>
    </contact>
    <investigator>
      <last_name>Amarilis Sanchez-Valle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University School of Medicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>12105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hilary Vernon, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marwan Shinawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai-Clinical Research Unit</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Graham-O'regan</last_name>
      <email>Katherine.Graham-oregan@mssm.edu</email>
    </contact>
    <contact_backup>
      <email>Kimihiko.Oishi@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kimihiko Oishi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Tumblin</last_name>
      <phone>412-692-5969</phone>
      <email>mark.tumblin2@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Gerard Vockley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Etienne Sokal, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Verloo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zentrum für Kinder- und Jugendmedizin Angelika-Lautenschläger-Klinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Jeltsch</last_name>
      <email>kathrin.jeltsch@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Thomas Opladen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trials in Medicine S.C.</name>
      <address>
        <city>Mexico City</city>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillermo Melendez Mier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Rosalia Flores Jurado, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Cruces</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luis Aldamiz-Echevarria Azuara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptial Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillem Pintos Morell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mercedes Gil Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eva Venegas Moreno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselpital, Universitaetsklinik fur Kinderheikunde</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Gautschi, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselpital, Universitätsklinik für Kinderheilkunde</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Gautschi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal Hospital</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M68HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Reena Sharma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Hospital for Neurology and Neurosurgery</name>
      <address>
        <city>London</city>
        <zip>WC1N3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Robin Lachmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microbiome</keyword>
  <keyword>Elevated Ammonia</keyword>
  <keyword>Disorder of the Urea Cycle Metabolism</keyword>
  <keyword>Urea Cycle Disorder</keyword>
  <keyword>KB195</keyword>
  <keyword>Kaleido</keyword>
  <keyword>UNLOCKED</keyword>
  <keyword>Ornithine Transcarbamylase Deficiency (OTC)</keyword>
  <keyword>Carbamoyl Phosphatase Synthetase 1 (CPS1)</keyword>
  <keyword>Argininosuccinic Acid Synthetase (ASS1)</keyword>
  <keyword>Argininosuccinic Acid Lyase (ASL)</keyword>
  <keyword>Arginase (ARG 1)</keyword>
  <keyword>N-acetyl Glutamate Synthetase (NAGS)</keyword>
  <keyword>Ornithine Translocase (ORNT1)</keyword>
  <keyword>Microbiome Metabolic Therapy (MMT)</keyword>
  <keyword>Glycan</keyword>
  <keyword>Nitrogen Binding Therapy (NBT)</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Oligosaccharide</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Glutamine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urea Cycle Disorders, Inborn</mesh_term>
    <mesh_term>Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

